Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

BACKGROUND: Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor th...

Descripción completa

Detalles Bibliográficos
Autores principales: Galili, Naomi, Tamayo, Pablo, Botvinnik, Olga B, Mesirov, Jill P, Brooks, Margarita R, Brown, Gail, Raza, Azra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407785/
https://www.ncbi.nlm.nih.gov/pubmed/22559819
http://dx.doi.org/10.1186/1756-8722-5-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407785/
https://www.ncbi.nlm.nih.gov/pubmed/22559819
http://dx.doi.org/10.1186/1756-8722-5-20

Ejemplares similares